恩替卡韦治疗耐拉米夫定的慢性乙型肝炎疗效观察

On clinical observation of the treatment of chronic Hepatitis B cases with resistance to lamivudine by entacavir

目的:观察恩替卡韦治疗耐拉米夫定的慢性乙型肝炎疗效。方法:将确诊耐拉米夫定的43例患者随机分为两组:对照组21例,继续使用拉米夫定及常规治疗,治疗组22例,在常规治疗的基础上停止使用拉米夫定,改用恩替卡韦0.5mg/d,治疗12个月,检测治疗前后两组患者的肝功能、"两对半"及HBV-DNA的变化情况。结果:两组治疗前后的肝功能、"两对半"及HBV-DNA的变化差异有显著性。结论:恩替卡韦治疗拉米夫定耐药的慢性乙肝患者,可在病毒学及生化学方面取得较好疗效,安全性好,值得临床进一步推广应用。

Objective：To observe the treatment of chronic Hepatitis B with resistance to lamivudine using entacavir. Methods： 43 patients were randomly divided into two groups： control group（21cases） were continued treatments with lamivudine and other conventional methods; experimental group （22 cases） were treated the cases with entacavir instead of lamivudine on the regular basis of conventional treatments （0.5 mg per day）.Afier 12 months of the two different types of treatments, detect the the changes of their liver function, serum HB markers and HBV-DNA of the two groups of patients. Resutlts：There were significant differences in the detections of liver function, HB markers and HBV-DNA between the two groups.Conclusion：A better therapeutic result could be achieved both virologically and bioehemieally by using enteeavir to treat the lamivudine-resistant patients with chronic Hepatitis B and this method is worthy to be further popularized.